** Shares of Hikal HIKA.NS fall 2.3% to 228.60 rupees
** Pharmaceutical co said on Friday that discrepancies in its revenue reporting spanning the last three quarters were identified during an internal fact-finding review
** Co suspects misconduct by employees in roles connected to sales and operational support
** If the irregularities had not occurred, sales would have been lower by approx 2% in Q4 FY25 and Q1 FY26 - Hikal
** Adds, that all the underlying sales are genuine and are backed by customer purchase orders
** YTD, HIKA down 41.5%
(Reporting by Urvi Dugar in Bengaluru)
((UrviManoj.Dugar@thomsonreuters.com;))